Literature DB >> 20439828

Elevated brain monoamine oxidase A binding in the early postpartum period.

Julia Sacher1, Alan A Wilson, Sylvain Houle, Pablo Rusjan, Sabrina Hassan, Peter M Bloomfield, Donna E Stewart, Jeffrey H Meyer.   

Abstract

CONTEXT: The early postpartum period is a time of high risk for a major depressive episode (or postpartum depression), with a prevalence of 13%. During this time, there is a heightened vulnerability for low mood because postpartum blues is common. Severe postpartum blues can herald the onset of postpartum depression. The neurobiological mechanisms to explain postpartum blues and the high risk for the onset of postpartum depression in the first few weeks after delivery are unclear. Estrogen levels drop 100- to 1000-fold during the first 3 to 4 days postpartum, and changes in estrogen levels have an inverse relationship with monoamine oxidase A (MAO-A) density. However, MAO-A levels have never been measured in the early postpartum period.
OBJECTIVE: To determine whether brain MAO-A binding is elevated in the early postpartum period.
DESIGN: Case-control study.
SETTING: Tertiary care academic psychiatric hospital in Toronto, Ontario, Canada. PARTICIPANTS: Fifteen healthy women who were 4 to 6 days postpartum and 15 healthy women who had not recently been postpartum underwent carbon 11-labeled harmine positron emission tomography scanning. All women were nonsmoking and medication free. MAIN OUTCOME MEASURE: MAO-A total distribution volume, an index of MAO-A density, was measured in prefrontal cortex, anterior cingulate cortex, anterior temporal cortex, thalamus, dorsal putamen, hippocampus, and midbrain.
RESULTS: MAO-A total distribution volume was significantly elevated (mean, 43%) throughout all analyzed brain regions during the early postpartum period.
CONCLUSIONS: Elevated MAO-A levels in the early postpartum period can be interpreted as a marker of a monoamine-lowering process that contributes to the mood change of postpartum blues. Rather than a purely psychosocial model, we propose a neurobiological model of estrogen decline, followed by elevated MAO-A binding, low mood, and subsequently a period of high risk for major depressive episodes. Our model has important implications for preventing postpartum depression and for developing therapeutic strategies that target or compensate for elevated MAO-A levels during postpartum blues.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20439828     DOI: 10.1001/archgenpsychiatry.2010.32

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  49 in total

Review 1.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 2.  Stress, sex hormones, inflammation, and major depressive disorder: Extending Social Signal Transduction Theory of Depression to account for sex differences in mood disorders.

Authors:  George M Slavich; Julia Sacher
Journal:  Psychopharmacology (Berl)       Date:  2019-07-29       Impact factor: 4.530

3.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

4.  Mechanistic role for a novel glucocorticoid-KLF11 (TIEG2) protein pathway in stress-induced monoamine oxidase A expression.

Authors:  Matthew Grunewald; Shakevia Johnson; Deyin Lu; Zhe Wang; Gwen Lomberk; Paul R Albert; Craig A Stockmeier; Jeffrey H Meyer; Raul Urrutia; Klaus A Miczek; Mark C Austin; Junming Wang; Ian A Paul; William L Woolverton; Seungmae Seo; Donald B Sittman; Xiao-Ming Ou
Journal:  J Biol Chem       Date:  2012-05-24       Impact factor: 5.157

Review 5.  Biological and psychosocial predictors of postpartum depression: systematic review and call for integration.

Authors:  Ilona S Yim; Lynlee R Tanner Stapleton; Christine M Guardino; Jennifer Hahn-Holbrook; Christine Dunkel Schetter
Journal:  Annu Rev Clin Psychol       Date:  2015       Impact factor: 18.561

Review 6.  Pharmacotherapy of postpartum depression: an update.

Authors:  Deborah R Kim; C Neill Epperson; Amy R Weiss; Katherine L Wisner
Journal:  Expert Opin Pharmacother       Date:  2014-04-29       Impact factor: 3.889

Review 7.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

Review 8.  Psychiatric consultation to the postpartum mother.

Authors:  Eleanor A Anderson; Deborah R Kim
Journal:  Curr Psychiatry Rep       Date:  2015-04       Impact factor: 5.285

Review 9.  Promising leads and pitfalls: a review of dietary supplements and hormone treatments to prevent postpartum blues and postpartum depression.

Authors:  Yekta Dowlati; Jeffrey H Meyer
Journal:  Arch Womens Ment Health       Date:  2020-11-17       Impact factor: 3.633

10.  The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.

Authors:  Shakevia Johnson; Shawna Tazik; Deyin Lu; Chandra Johnson; Moussa B H Youdim; Junming Wang; Grazyna Rajkowska; Xiao-Ming Ou
Journal:  Front Neurosci       Date:  2010-11-02       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.